When the blood flow to a part of the brain is reduced or interrupted, the neurological function losses that occur as a result of the inability of the brain vessels to be fed are called stroke (stroke).
It is possible to minimize the risk of stroke by taking measures such as being at an ideal weight, consuming healthy foods, leading an active life, and staying away from harmful habits such as smoking and alcohol. When a stroke occurs, brain cells begin to die within minutes, and as a result, the dying brain cells cannot be regenerated. For this reason, emergency intervention is of vital importance for this disease, which can be prevented in the early period.
The KinG Vascular Revascularization Device, developed in Invamed R&D laboratories and produced on the production campus, offers an innovative technology for rapid endovascular treatment. KinG Vascular Revascularization Device, which is exported to many countries of the world, provides effective and successful clinical results. According to the statement made by Invamed; The KinG Vascular Revascularization Device clears the blocking thrombus (blood clots) and rejuvenates neurological tissue by improving blood flow. Also in the statement; It is stated that KinG Vascular is designed to restore blood flow in patients who have had an ischemic stroke due to large intracranial vascular occlusion.
17 million people worldwide have a stroke each year.
Every year, 17 million people worldwide have a stroke. This statistic means that almost every 1 person has a stroke per minute. 6 million of stroke patients die. In addition, stroke can cause permanent damage to many people. In Turkey, it is seen that approximately 140 thousand people have a stroke and the number of people who lost their lives as a result of stroke is between 35 thousand and 40 thousand. Stroke with different symptoms; It can manifest itself with speech disorders, severe headache, sudden unilateral weakness or depersonalization of a part of the body. Stroke, which can be seen in all age groups, is most common in men over the age of 60.
